NEW YORK, NY--(Marketwire -08\/08\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) are up roughly 32 percent for the year, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on ISIS Pharmaceuticals, Inc. (ISIS) and Achillion Pharmaceuticals, Inc. (ACHN). <\/p>\n
Access to the full company reports can be found at: <\/p>\n
http:\/\/www.ParagonReport.com\/ISIS<\/a> <\/p>\n http:\/\/www.ParagonReport.com\/ACHN<\/a> <\/p>\n Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.ParagonReport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. The company reported revenues for the three months ended June 30, 2012 were $47.3 million, nearly double the total for the same period in 2011. <\/p>\n Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: <\/p>\n http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Follow this link: NEW YORK, NY--(Marketwire -08\/08\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) are up roughly 32 percent for the year, outperforming the broader market by a wide margin. Continue reading
\nBiotech Industry Soaring in 2012 -- ISIS Pharmaceuticals Surges on Strong Results<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"